Turnstone biologics presents preclinical data highlighting potential for selected tumor-infiltrating lymphocyte (til) therapy in solid tumors at the 2023 society for immunotherapy of cancer (sitc) annual meeting

Posters showcase turnstone's novel selected til programs which are designed to selectively expand the most potent tumor-reactive t cells for solid tumors.
TSBX Ratings Summary
TSBX Quant Ranking